Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 79 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationStatus unknownNCT02961270Phase 2
- Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedNCT02960945Phase 1
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLCStatus unknownNCT02960607Phase 2
- Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerCompletedNCT02959749Phase 2/3
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
- Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
- Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled TrialStatus unknownNCT02951637Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2
- A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
- Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.CompletedNCT02945852Phase 2
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck CancerStatus unknownNCT02943252Phase 2
- Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic CarcinomaStatus unknownNCT02942693Phase 2
- Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric CancerStatus unknownNCT02942329Phase 1/2
- Study of Ixazomib and Erlotinib in Solid TumorsCompletedNCT02942095Phase 1
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2
- Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaCompletedNCT02935309Phase 1
- Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02934256Phase 2
- Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
- Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
- Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With GlioblastomaStatus unknownNCT02928575Phase 2
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsStatus unknownNCT02927340Phase 2
- Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsCompletedNCT02926768Phase 1
- Regorafenib in Relapsed GlioblastomaCompletedNCT02926222Phase 2
- A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.CompletedNCT02925104Phase 1
- Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.CompletedNCT02922777Phase 1
- Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)Status unknownNCT02919371Phase 1/2
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsActive, not recruitingNCT02917720Phase 2
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
- Kanitinib in Treating Patients With Advanced Solid TumorsCompletedNCT02916095Phase 1
- Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
- Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
- Safety and Activity of SNX-5422 Plus Ibrutinib in CLLWithdrawnNCT02914327Phase 1
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsCompletedNCT02913716Phase 1
- Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
- Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
- Relieving Chronic Itch: Oral MedicationWithdrawnNCT02909569Phase 2
- Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
- Curcumin Supplement in Nonalcoholic Fatty Liver PatientsCompletedNCT02908152Phase 2/3
- Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerCompletedNCT02906059Phase 1
- Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2
- First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001CompletedNCT02896231Phase 1
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy SubjectsStatus unknownNCT02892370Phase 1
- Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
- Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
- Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3
- Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsCompletedNCT02889328Phase 2
- Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic LeukemiaCompletedNCT02888990Phase 2
- EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT02886195Phase 3
- Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL GeneStatus unknownNCT02885766Phase 1/2
- Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric CarcinomaStatus unknownNCT02884453Phase 2
- First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationStatus unknownNCT02883543Phase 3
- Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA CapsuleCompletedNCT02877225Phase 1
- Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor ComplexWithdrawnNCT02876081Phase 2
- Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/CisplatinStatus unknownNCT02875457Phase 3
- Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human TrialCompletedNCT02874989Phase 1
- ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Phase 2
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
- Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian CancerCompletedNCT02867956Phase 2
- Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical ResectionTerminatedNCT02867280Phase 3
- Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumStatus unknownNCT02866370Phase 2
- Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease ProgressionCompletedNCT02863718Phase 3
- A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic CancerStatus unknownNCT02863367Phase 2
- Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaTerminatedNCT02863055Phase 2
- Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2
- A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT02859948Phase 1
- EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT02859077Phase 3
- Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaCompletedNCT02859012Phase 2
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
- A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired SubjectsCompletedNCT02857868Phase 1
- Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14CompletedNCT02857712Phase 2
- Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)WithdrawnNCT02856867Phase 2
- Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1
- Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy VolunteersCompletedNCT02853643Phase 1
- Apatinib and Irinotecan in Treating Patients With Recurrent High-grade GliomaStatus unknownNCT02848794Phase 1/2
- Glutathione vs. Curcumin Clinical TrialStatus unknownNCT02848417Phase 1/2
- Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTStatus unknownNCT02847429Phase 3
- Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR SignalingWithdrawnNCT02846766Phase 2
- Study of Apatinib and MASCT in Patients With Advanced Solid TumorsStatus unknownNCT02844881Phase 1/2
- Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA CapsulesCompletedNCT02841150Phase 1
- A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02838264Phase 1
- Effect of Rifampicin on the Pharmacokinetics of ApatinibCompletedNCT02836821Phase 1
- Effect of Itraconazole on the Pharmacokinetics of ApatinibCompletedNCT02836171Phase 1
- Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRCCompletedNCT02835924Phase 2
- Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsCompletedNCT02835833Phase 1
- A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 MutationCompletedNCT02834936Phase 2
- Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2